KFU. Card publication. Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis

KAZAN
FEDERAL UNIVERSITY

- RUS
- 中文
- ES

MODULATING INNATE AND ADAPTIVE IMMUNITY BY (R)-ROSCOVITINE: POTENTIAL THERAPEUTIC OPPORTUNITY IN CYSTIC FIBROSIS

Form of presentation

Articles in international journals and collections

Year of publication

2016

��

��

Authors, employees of KFU

Gabdulkhakova Aida Gabdrakhmanovna, author

Bibliographic description in the original language

Meijer L. Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis. / Nelson DJ, Riazanski V, Gabdoulkhakova AG, Hery-Arnaud G, Le Berre R, Loaëc N, Oumata N, Galons H, Nowak E, Gueganton L, Dorothée G, Prochazkova M, Hall B, Kulkarni AB, Gray RD, Rossi AG, Witko-Sarsat V, Norez C, Becq F, Ravel D, Mottier D, Rault G. // J Innate Immun. - 2016. - 8(4): P. 330-49. doi: 10.1159/000444256.

Annotation

Journal of innate immunity

Keywords

Roscovitine, Seliciclib, TRPC6, CFTR, Corrector, Cystic fibrosis, Infection, Inflammation, Innate immunity, Pseudomonas aeruginosa

The name of the journal

J Innate Immun

URL

https://www.karger.com/Article/FullText/444256

Please use this ID to quote from or refer to the card

https://repository.kpfu.ru/eng/?p_id=144093&p_lang=2

Resource files

File name	Size (MB)	Format
2016_LMeijer.pdf	3,30	pdf	show / download

Full metadata record

Field DC	Value	Language
dc.contributor.author	Gabdulkhakova Aida Gabdrakhmanovna	ru_RU
dc.date.accessioned	2016-01-01T00:00:00Z	ru_RU
dc.date.available	2016-01-01T00:00:00Z	ru_RU
dc.date.issued	2016	ru_RU
dc.identifier.citation	Meijer L. Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis. / Nelson DJ, Riazanski V, Gabdoulkhakova AG, Hery-Arnaud G, Le Berre R, Loaëc N, Oumata N, Galons H, Nowak E, Gueganton L, Dorothée G, Prochazkova M, Hall B, Kulkarni AB, Gray RD, Rossi AG, Witko-Sarsat V, Norez C, Becq F, Ravel D, Mottier D, Rault G. // J Innate Immun. - 2016. - 8(4): P. 330-49. doi: 10.1159/000444256.	ru_RU
dc.identifier.uri	https://repository.kpfu.ru/eng/?p_id=144093&p_lang=2	ru_RU
dc.description.abstract	J Innate Immun	ru_RU
dc.description.abstract	Journal of innate immunity	ru_RU
dc.description.abstract	(R)-Roscovitine, a pharmacological inhibitor of kinases, is currently in phase II clinical trial as a drug candidate for the treatment of cancers, Cushing's disease and rheumatoid arthritis. We here review the data that support the investigation of (R)-roscovitine as a potential therapeutic agent for the treatment of cystic fibrosis (CF). (R)-Roscovitine displays four independent properties that may favorably combine against CF: (1) it partially protects F508del-CFTR from proteolytic degradation and favors its trafficking to the plasma membrane; (2) by increasing membrane targeting of the TRPC6 ion channel, it rescues acidification in phagolysosomes of CF alveolar macrophages (which show abnormally high pH) and consequently restores their bactericidal activity; (3) its effects on neutrophils (induction of apoptosis), eosinophils (inhibition of degranulation/induction of apoptosis) and lymphocytes (modification of the Th17/Treg balance in favor of the differentiation of anti-inflammator	ru_RU
dc.language.iso	ru	ru_RU
dc.subject	Roscovitine	ru_RU
dc.subject	Seliciclib	ru_RU
dc.subject	TRPC6	ru_RU
dc.subject	CFTR	ru_RU
dc.subject	Corrector	ru_RU
dc.subject	Cystic fibrosis	ru_RU
dc.subject	Infection	ru_RU
dc.subject	Inflammation	ru_RU
dc.subject	Innate immunity	ru_RU
dc.subject	Pseudomonas aeruginosa	ru_RU
dc.title	Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis	ru_RU
dc.type	Articles in international journals and collections	ru_RU